Q-omics provides the consensus-scored SPAG17 profile across patient tissues and cancer cell-line models. SPAG17 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SPAG17 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, SPAG17 RNA expression shows 16,767 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where SPAG17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPAG17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPAG17 survival associations across molecular data types. SPAG17 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPAG17 RNA expression–survival associations across cancer types. High SPAG17 expression shows unfavorable associations in DLBC, LGG and KIRC, but favorable associations in ACC, READ and UCS. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SPAG17 RNA expression.
This table summarizes SPAG17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SPAG17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPAG17 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, COAD, CHOL and PAAD. The KICH box plot shows higher SPAG17 RNA expression in normal versus tumor tissue (log2 FC = −1.257, t-test p < 0.001).
This table shows molecular features associated with SPAG17 in patient tissues and cancer cell lines. In patient samples, SPAG17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SPAG17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
